Literature DB >> 10356257

Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans.

J M Le Doux1, J R Morgan, M L Yarmush.   

Abstract

We have previously shown that the efficiency of retrovirus-mediated gene transfer is limited in part due to the presence of chondroitin sulfate proteoglycans in virus stocks. In this study, we have used a model recombinant retrovirus encoding the Escherichia coli lacZ gene, bovine aorta chondroitin sulfate proteoglycan (CSPG), various free glycosaminoglycan chains (GAGs), and quantitative assays for retrovirus transduction to explore the mechanism by which proteoglycans and glycosaminoglycans inhibit retroviruses. We found that CSPG and GAGs block an early step in virus-cell interactions but do not act by inactivating viruses or by reducing the growth rate of the target cells. CSPG and most of the GAGs tested (chondroitin sulfate A, chondroitin sulfate B, heparin, heparan sulfate, and hyaluronic acid) inhibited transduction, but with widely varying degrees of activity. The chemical structure of GAGs was found to be an important determinant of their inhibitory activity, which suggests that GAGs do not inhibit transduction simply because they are highly negatively charged polymers. When GAGs were used in combination with a cationic polymer (Polybrene), however, their inhibitory activity was neutralized, and interestingly, at optimal doses of GAG and Polybrene, transduction efficiency was actually enhanced by as much as 72%. In contrast, the inhibitory activity of CSPG, due to the influence of its core protein, was not substantially reduced by Polybrene. The importance of these findings to our understanding of retrovirus-cell interactions and to the development of more efficient retrovirus gene transfer protocols is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356257     DOI: 10.1021/bp990049c

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  7 in total

1.  A unique heparin-binding domain in the envelope protein of the neuropathogenic PVC-211 murine leukemia virus may contribute to its brain capillary endothelial cell tropism.

Authors:  A Jinno-Oue; M Oue; S K Ruscetti
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.

Authors:  Nina Dmitrieva; Lianbo Yu; Mariano Viapiano; Timothy P Cripe; E Antonio Chiocca; Joseph C Glorioso; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2010-12-21       Impact factor: 12.531

3.  Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection.

Authors:  Simon J Walker; Massimo Pizzato; Yasuhiro Takeuchi; Stephen Devereux
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

4.  Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation.

Authors:  Howard E Davis; Matthew Rosinski; Jeffrey R Morgan; Martin L Yarmush
Journal:  Biophys J       Date:  2004-02       Impact factor: 4.033

5.  Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer.

Authors:  Helen Gosnell; Laura M Kasman; Thrimoorthy Potta; Lucas Vu; Elizabeth Garrett-Mayer; Kaushal Rege; Christina Voelkel-Johnson
Journal:  J Control Release       Date:  2013-12-24       Impact factor: 9.776

6.  In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid.

Authors:  Claudio Cermelli; Alessandro Cuoghi; Monica Scuri; Clotilde Bettua; Rachele G Neglia; Andrea Ardizzoni; Elisabetta Blasi; Tommaso Iannitti; Beniamino Palmieri
Journal:  Virol J       Date:  2011-03-25       Impact factor: 4.099

7.  Efficient production of inhibitor-free foamy virus glycoprotein-containing retroviral vectors by proteoglycan-deficient packaging cells.

Authors:  Clara Marie Munz; Henriette Kreher; Alexander Erdbeer; Stefanie Richter; Dana Westphal; Buqing Yi; Rayk Behrendt; Nicole Stanke; Fabian Lindel; Dirk Lindemann
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-01       Impact factor: 5.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.